OriGene Takes Over Pathology Reagent Company Zhongshan Golden Bridge Biotechnology
ZsBio was established in 1993 and is based in Beijing.!--h2>
OriGene Technologies is purchasing Zhongshan Golden Bridge Biotechnology to bolster its position in the Chinese pathology testing market. The Chinese pathology testing market has been experiencing double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry, according to OriGene.
Headquartered in Beijing since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market. "With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene," says Wei-Wu He, CEO of OriGene.
"ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative, highly specific monoclonal antibodies and assays to complement and strengthen ZsBio's portfolio of products."
OriGene is dedicated to developing gene-centric products and services to improve the quality of healthcare diagnostics and treatments. The company last made an acquisition in August 2010, when it picked up Blue Heron Biotechnology, a gene synthesis firm established in 1999. Back in October 2009, OriGene took over Marligen Biosciences, securing a range of protein and gene-expression profiling assays and testing services.
OriGene couples its assays and reagents with its high-throughput mAb production capabilities. The company is developing its TrueMAB collection of monoclonal antibodies, which consists of antibodies that are significantly different from many on the market, as OriGene will be using authentic human full-length proteins as immunogens during the manufacturing process, the company points out. Over the last decade OriGene has built what it believes to be the largest collection of human full-length cDNA clones in the world.
In February 2009 it obtained $6.5 million to complete the acquisition of Shenzhen P&A Biotech, a manufacturer and provider of mAbs. With the establishment of this technology center, OriGene said that it would be able to develop genome-wide mAbs.